Xeris Biopharma Holdings (XERS) Short-term Investments (2020 - 2024)

Xeris Biopharma Holdings' Short-term Investments history runs 5 years deep, the most recent figure standing at $10.2 million for Q3 2024.

• Quarterly Short-term Investments fell 48.72% year-over-year to $10.2 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $10.2 million (down 48.72% YoY) and the FY2023 annual result came in at $5.0 million, changed N/A from the prior year.
• Short-term Investments was $10.2 million for Q3 2024 at Xeris Biopharma Holdings, down from $20.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $96.2 million in Q4 2020 and bottomed at $5.0 million in Q4 2023.
• A 5-year average of $29.0 million and a median of $24.7 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments slumped 72.16% — and 2023, when it surged 112.78%.
• Xeris Biopharma Holdings' Short-term Investments stood at $96.2 million in 2020, then slumped by 63.45% to $35.2 million in 2021, then sank by 73.48% to $9.3 million in 2022, then plunged by 46.35% to $5.0 million in 2023, then soared by 103.32% to $10.2 million in 2024.
• Business Quant data shows XERS's Short-term Investments at $10.2 million in Q3 2024, $20.0 million in Q2 2024, and $24.7 million in Q1 2024.